Treatment of gait disorders in Parkinson’s disease;Tratamiento de los trastornos de la marcha en la enfermedad de Parkinson

Revista de Neurologia

Volumn 54, Issue , 2012, Pages S61-S68

  Santos, H ^a   Garcia Antelo M J ^b   Ivanovic Barbeito Y ^c,d   Diaz Silva J J ^e   Sobrido, María Jesús ^f  

^a HOSPITAL SAN RAFAEL   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Centro médico de rehabilitación Monte Alto   (Spain)

^d TELEFONICA RESEARCH   (Spain)

^e USP Hospital Santa Teresa   (Spain)

^f Instituto de Investigación Sanitaria de Santiago de Compostela IDIS   (Spain)

Author keywords

Deep brain stimulation; Gait disorders; Medical treatment; Parkinson s disease; Pathophysiology; Physiotherapy

Indexed keywords

3,4 DIHYDROXYPHENYLSERINE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; MEMANTINE; METHYLPHENIDATE; NEUROTRANSMITTER; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ACUPUNCTURE; ARTICLE; BODY POSTURE; BRAIN DEPTH STIMULATION; EMOTIONALITY; ENVIRONMENTAL FACTOR; EXECUTIVE FUNCTION; GAIT DISORDER; HUMAN; HYPOKINESIA; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PHYSIOTHERAPY; PROPRIOCEPTIVE FEEDBACK; QUALITY OF LIFE; SUBTHALAMIC NUCLEUS; WALKING;

EID: 84876185205     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE; Parkinson Study Group DATATOP investigators. Predictors of deterioration in Health-related quality of life in Parkinson/s disease: results from the DATATOP trial. Mov Disord 2008; 23: 653-9.
2. Clissold BG, McColl CD, Reardon KA, Shiff M, Kempster PA. Longitudinal study of the motor response to levodopa in Parkinson/s disease. Mov Disord 2006; 21: 2116-21.
3. Hausdorff JM. Gait dynamics in Parkinson/s disease: Common and distinct behaviour among stride length, gait variability and fractal-like scaling. Chaos 2009; 19: 026113.
4. Boonstra TA, van der Kooij H, Munneke M, Bloem BR. Gait disorders and balance disturbances in Parkinson/s disease: clinical update and pathophysiology. Curr Oppin Neurol 2008; 21: 461-71.
5. Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 2011; 10: 734-44.
6. Lim SY, Fox SH, Lang AE. Overview of the Extranigral Aspects of Parkinson Disease. Arch Neurol 2009; 66: 167-72.
7. Takakusaki K, Tomita N, Yano M. Substrates for normal gait and pathophysiology of gait disturbances with respect to the basal ganglia dysfunction. J Neurol 2008; 255: S19-29.
8. Devos D, Defebvre L, Bordet R. Dopaminergic and nondopaminergic pharmacological hypotheses for gait disorders in Parkinson/s disease. Fundam Clin Pharmacol 2010, 24: 407-21.
9. Grimbergen YA, Langston JW, Roos R AC, Bloem BR. Postural instability in Parkinson/s disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 2009; 9: 279-90.
10. Plotnik M, Hausdorff JM. The role of gait rhitmicity and bilateral coordination of stepping in the Pathophysiology of freezing of gait in Parkinson/s disease. Mov Disord 2008; 23: S444-50.
11. Hallet M. The intrinsic and extrinsic aspects of freezing of gait. Mov Disord 2008; 22: S439-43.
12. Morris ME, Iansek R, Galna B. Gait festination and freezing in Parkinson/s disease: Pathogenesis and Rehabilitation. Mov Disord 2008; 23: S451-60.
13. Moris-De la Tassa G, Arias-Rodriguez M. Tratamiento de los sintomas motores en la enfermedad de Parkinson. Rev Neurol 2009; 48: S27-S31.
14. Wright WG, Gurfinkel VS, King LA, Nutt JG, PJ Cordo, Horak FB. Axial kinaesthesia is impaired in Parkinson/s disease: Effects of levodopa. Exp Neurol 2010; 225: 202-9.
15. Almeida QJ, Frank JS, Roy EA, Patla AE, Jog MS. Dopaminergic modulation of timing control and variability in the gait of Parkinson/s disease. Mov Disord 2007; 22: 1735-42.
16. Antonini A, Ursino G, Calandrella D, Plebani M. Continuous dopaminergic delivery in Parkinson/s disease. J Neurol 2010; 257: S305-8.
17. Alonso Canovas A, Luquin Piudo R, Garcia Ruiz-Espiga, Burguera JA, Campos Arillo V, Castro A, et al. Agonistas dopaminergicos en la enfermedad de Parkinson. Neurologia 2011 Jul 1. [Epub ahead of print]
18. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five year study of the incidence of dyskinesia in patients with early Parkinson/s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91.
19. Giladi N. Medical treatment of freezing of gait. Mov Disord 2008; 23: S482-8.
20. EASE-PD Adjunct Study Investigators. Ropinirol 24-hour prolonged release. Randomized controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-15.
21. Hametner EM, Seppi K, Poewe W. Pramipexole extended release in Parkinson’s disease. Expert Rev Neurother 2011;11: 1229-34.
22. Ruiz-Huete C, Bermejo PE, Terron C, Anciones B. Rotigotina en el tratamiento de la enfermedad de Parkinson. Experiencia sobre una muestra de 150 pacientes. Rev Neurol 2008; 46: 257-60.
23. Pagonabarraga J, Kulisevsky J. Rasagilina: eficacia y proteccion en la enfermedad de Parkinson. Rev Neurol 2010; 51: 535-41.
24. Hauser RA. Future Treatments for Parkinson/s disease: Surfing the PD pipeline. Int J Neurosci 2011; 121: S53-62.
25. Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebocontrolled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord 2011 Sep 12. [Epub ahead of print]
26. Espay AJ, Dwivedi AK, Payne M, Gaines L, Vaughan JE, Maddux BN, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011; 76:1256-62.
27. Jancovik J. Atomoxetine for freezing of gate in Parkinson disease. J Neurol Sci 2009; 284:177-8.
28. Macht M, Kaussner Y, Moller JC, Stiasny-Kolster K, Eggert KM, Kruger HP, et al. Predictors of freezing in Parkinson’s disease: a survey of 6,620 patients. Mov Disord 2007; 22: 953-6.
29. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263-69.
30. Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 2005; 65: 626-28.
31. Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type A into the calf muscles on freezing of gait in Parkinson/s disease: a double blind placebo-controlled pilot study. Mov Disord 2007; 22: 880-3.
32. Wharen R. Clinical effects of deep brain stimulation on gait disorders in Parkinson/s disease. Eur J Neurol 2010; 17: 639-40.
33. Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson J, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002; 59: 932-4.
34. Bakker M, Esselink AJ, Munneke M, Limousin-Dowsey P, Speelman HD, Bloem BR. Effects of stereotactic neurosurgery on postural instability and gait in Parkinson/s disease. Mov Disord 2004; 19: 1092-9.
35. Plaha P, Ben-Shlomo Y, Patel NK, Gill SS. Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain 2006; 129: 1732-47.
36. Lee KH, Blaha CD, Garris PA, Cooper S, Hitti FL, Leiter JC, et al. Evolution of deep brain stimulation: human electrometer and smart devices supporting the next generation of therapy. Neuromodulation 2009; 12: 85-103.
37. Johnsen EL, Sunde N, Mogensen PH, Ostergaard K. MRI verified STN stimulation site-gait improvement and clinical outcome. Eur J Neurol 2010; 17(5): 746-53.
38. Moreau C, Defebvre L, Destee A, Bleuse S, Clement F, Blatt JL, et al. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology 2008; 71: 80-4.
39. Guridi J, Rodriguez-Oroz MC, Clavero P, Manrique M. Revision critica de la estimulacion subtalamica en la enfermedad de Parkinson. Neurocirugia. 2009; 20: 521-32.
40. St George RJ, Nutt JG, Burchiel KJ, Horak FB. A metaregression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010; 75: 1292-9.
41. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson/s disease. Brain 2000; 123: 1767-83.
42. Khan S, Mooney L, Plaha P, Javed S, White P, Whone AL, et al. Outcomes from stimulation of the caudal zona incerta and pedunculopontine nucleus in patients with Parkinson’s disease. Neurosurgery 2011; 25:273-80.
43. Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, et al. Bilateral deep brain stimulation of pedunculopontine and subthalamic nuclei in severe Parkinson/s disease. Brain 2007; 130: 1596-607.
44. Ferraye MU, Debu B, Fraix V, Xie-Brustolin J, Chabardes S, Krack P, et al. Effects of subthalamic stimulation and levodopa on freezing of gait in Parkinson/s disease. Neurology 2008; 70: 1431-7.
45. Morris ME, Martin CL, Schenkman ML. Striding out with Parkinson disease: Evidence-based Physical Therapy for Gait disorders. Phys Ther 2010; 90: 280-8.
46. MacMahon DG, Fletcher P, Thomas S, Lee M. Parkinson’s disease Diagnosis and Management in Primary and Secondary care NICE Guideline Draft for second consultation 2006 National Collaborating Centre for Chronic Conditions Royal College of Physicians London. URL: http://www.nice.org.uk/pdf/parkinsons_ secondconsultation_Full_guideline.pdf. [20.11.2011]
47. Findley L, Peto V, Pugner K. The impact of Parkinson’s disease on quality of life: results of a research survey in the UK. Mov Disord 2000; 15: S179.
48. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology and treatment of depression in Parkinson’s disease. Biol Psychiatry 2003; 54: 363-75.
49. Niewboer A. Cueing for Freezing of Gait in Patients with Parkinson/s Disease: A Rehabilitation Perspective. Mov Disord 2008; 23: S475-81.
50. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002; 17: 867-76.
51. Thompson JA. Rehabilitation for patients with Parkinson' disease. Lancet 2001; 357: 410-1.
52. De Goede CJ, Keus SH, Kwakkel G, Wagenaar RC. The effects of Physical Therapy in Parkinson’s disease: a research synthesis. Arch Phys Med Rehabil 2001; 82: 509-15.
53. Nieuwboer A, Kwakkei G, Rochester L, Jones D, van Wegen E, Willems AM, et al. Cueing training in the home improves gait-related mobility in Parkinson/s disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007; 78: 134-40.
54. Werner WG, Gentile AM. Improving gait and promoting retention in individuals with Parkinson/s disease: a pilot study. J Neurol 2010; 257: 1841-7.
55. Mehrholz J, Friis R, Kugler J, Twork S, Storch A, Pohl M. Treadmill training for patients with Parkinson/s disease. Cochrane Database Syst Rev. 2010; (1):CD007830.
56. Herman T, Giladi N, Hausdorff JM. Treadmill training for the treatment of gait disturbances in people with Parkinson’s disease: a mini-review. J Neural Transm 2009; 116: 307-18.
57. Lin Y, Lin X. Comparative study of D2 receptors and dopamine content in striatum before and after electro acupuncture treatment in rats. Chin Med J (Engl) 2000; 113: 408-11.
58. Zhu JM, Xia Y, Cao XD. Effects of noradrenaline and dopamine in preoptic area on acupuncture analgesia. Acupuncture Research 15: 117-122.
59. Shulman, LM, Wen X, Weiner WJ, Bateman, D, Minagar A, Duncan R, et al. Acupuncture therapy for the symptoms of Parkinson’s disease. Mov Disord 2002; 17: 799-802.
60. Lee MS, Shin BC, Kong JC, Ernst E. Effectiveness of acupuncture for Parkinson’s disease: A systematic review. Mov Disord 2008; 23: 1505-15.
61. Streitberger K, Kleinhenz J. Introducing a placebo needle into acupuncture research. Lancet 1998; 352: 364-5.
62. Kaptchuk TJ. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med 1998; 72: 389-433.